TP53 and neoplasm: An important study conducted by Yasukawa revealed the importance of the anti-tumor effects of PARP inhibitors used in combination with chemotherapeutic agents such as cisplatin thanks to their abilities to arrest cell cycle and decrease DNA repair activity through a G2 cell-cycle arrest-like effect in a dose and p53-dependent manner [21,22].